| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.75▼ | 5.74▲ | 5.73▲ | 5.41▲ | 5.02▲ |
| MA10 | 5.74▼ | 5.72▲ | 5.67▲ | 5.37▲ | 5.08▲ |
| MA20 | 5.73▲ | 5.62▲ | 5.46▲ | 5.01▲ | 5.08▲ |
| MA50 | 5.54▲ | 5.40▲ | 5.42▲ | 5.09▲ | 7.63▼ |
| MA100 | 5.40▲ | 5.36▲ | 5.12▲ | 5.05▲ | 10.33▼ |
| MA200 | 5.37▲ | 5.00▲ | 4.97▲ | 7.01▼ | 65.93▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.009▼ | 0.003▲ | 0.037▲ | 0.081▲ | 0.224▲ |
| RSI | 60.178▲ | 63.928▲ | 63.287▲ | 60.411▲ | 47.915▼ |
| STOCH | 83.611▲ | 69.973 | 82.904▲ | 67.015 | 43.447 |
| WILL %R | -30.000 | -25.806 | -12.121▲ | -8.019▲ | -19.000▲ |
| CCI | 33.333 | 63.378 | 78.911 | 119.322▲ | 111.252▲ |
|
Tuesday, April 29, 2025 04:01 AM
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 5.69 | 5.8499 | 5.502 | 5.72 | 125,463 |
| 30/04/25 | 5.20 | 5.64 | 5.0987 | 5.64 | 137,983 |
| 29/04/25 | 5.175 | 5.34 | 5.175 | 5.24 | 303,168 |
| 28/04/25 | 5.24 | 5.405 | 5.02 | 5.11 | 80,388 |
| 25/04/25 | 5.49 | 5.6761 | 5.16 | 5.33 | 69,472 |
| 24/04/25 | 5.61 | 5.685 | 5.41 | 5.50 | 85,405 |
| 23/04/25 | 5.44 | 5.75 | 5.40 | 5.68 | 187,201 |
| 22/04/25 | 5.15 | 5.44 | 5.09 | 5.32 | 97,462 |
| 21/04/25 | 4.95 | 5.245 | 4.95 | 5.13 | 62,249 |
| 17/04/25 | 5.01 | 5.15 | 4.90 | 5.02 | 99,004 |
|
|
||||
|
|
||||
|
|